UGT1A1 and colonic neoplasm: The NCCN colon cancer guidelines advise caution and suggest alternative dosing strategies for UGT1A1 poor metabolizers (UGT1A*28 homozygous variants) scheduled to receive irinotecan; however, no testing guidelines have been established [19,20].